@Article{or.2026.085229,
AUTHOR = {Shih-Wei Chiang, Ming-Cheng Chen, Chang-Lin Lin, Yi-Lin Huang, Feng-Fan Chiang, Shun-Fa Yang},
TITLE = {Differential Tumor Response and Conversion Outcomes Associated with First-Line Biologic Strategies in Liver-Limited <i>RAS</i> Wild-Type Metastatic Colorectal Cancer},
JOURNAL = {Oncology Research},
VOLUME = {},
YEAR = {},
NUMBER = {},
PAGES = {{pages}},
URL = {http://www.techscience.com/or/online/detail/27761},
ISSN = {1555-3906},
ABSTRACT = {<b>Background:</b> Anti-EGFR therapy is widely used as first-line treatment for <i>RAS</i> wild-type metastatic colorectal cancer (mCRC), particularly in patients with left-sided tumors. In liver-limited disease, maximizing tumor shrinkage may facilitate conversion to resectability; however, comparative real-world evidence among panitumumab, cetuximab, and bevacizumab remains limited. This study aimed to compare the clinical outcomes of these biologic agents in patients with <i>RAS</i> wild-type mCRC. <b>Methods:</b> We retrospectively analyzed 241 patients with <i>RAS</i> wild-type mCRC treated with first-line chemotherapy plus panitumumab (<i>n</i> = 76), cetuximab (<i>n</i> = 80), or bevacizumab (<i>n</i> = 85) between 2016 and 2024. Outcomes included depth of response (DpR), objective response rate (ORR), disease control rate (DCR), conversion surgery rate, progression-free survival (PFS), and overall survival (OS). <b>Results:</b> Overall, panitumumab demonstrated superior tumor response, achieving the highest ORR (69.7%) and conversion surgery rate (34.2%), although PFS and OS were comparable among treatment groups. In patients with liver-limited disease, panitumumab was associated with a higher conversion surgery rate than bevacizumab (50.0% vs. 19.4%) and a trend toward longer OS. Right-sided primary tumors and <i>BRAF</i> mutation remained independent predictors of poorer OS. <b>Conclusions:</b> Panitumumab-based therapy was associated with deeper tumor shrinkage and higher conversion rates, particularly in liver-limited mCRC. These findings suggest that greater cytoreduction may increase opportunities for local treatment in selected patients. However, given the retrospective nature of the study, the findings should be considered hypothesis-generating and require prospective validation.},
DOI = {10.32604/or.2026.085229}
}